Advertisement

Treatment of WHO Grade 2 Meningiomas With Stereotactic Radiosurgery: Identification of an Optimal Group for SRS Using RPA

Published:February 02, 2021DOI:https://doi.org/10.1016/j.ijrobp.2021.01.048

      Purpose

      This study assesses a large multi-institutional database to present the outcomes of World Health Organization grade 2 meningiomas treated with stereotactic radiosurgery (SRS). We also compare the 3-year progression-free survival (PFS) to that reported in the Radiation Therapy Oncology Group 0539 phase 2 cooperative group meningioma trial.

      Methods and Materials

      From an international, multicenter group, data were collected for grade 2 meningioma patients treated with SRS for demonstrable tumor from 1994 to 2019. Statistical methods used included the Kaplan-Meier method, Cox proportional hazards analysis, and recursive partitioning analysis.

      Results

      Two hundred thirty-three patients treated at 12 institutions were included. Patients presented at a median age of 60 years (range, 13-90), and many had at least 2 prior resections (30%) or radiation therapy (22%). Forty-eight percent of patients had prior gross total resection. At SRS, the median treatment volume was 6.1 cm3 (0.1-97.6). A median 15 Gy (10-30) was delivered to a median percent isodose of 50 (30-80), most commonly in 1 fraction (95%). A model was developed using recursive partitioning analysis, with one point attributed to age >50 years, treatment volume >11.5 cm3, and prior radiation therapy or multiple surgeries. The good-prognostic group (score, 0-1) had improved PFS (P < .005) and time to local failure (P < .005) relative to the poor-prognostic group (score, 2-3). Age >50 years (hazard ratio = 1.85 [95% confidence interval, 1.09-3.14]) and multiple prior surgeries (hazard ratio = 1.80 [1.09-2.99]) also portended reduced PFS in patients without prior radiation therapy. Two hundred eighteen of 233 patients in this study qualified for the high-risk group of Radiation Therapy Oncology Group 0539, and they demonstrated similar outcomes (3-year PFS: 53.9% vs 58.8%). The good-prognostic group of SRS patients demonstrated slightly improved outcomes (3-year PFS: 63.1% vs 58.8%).

      Conclusions

      SRS should be considered in carefully selected patients with atypical meningiomas. We suggest the use of our good-prognostic group to optimize patient selection, and we strongly encourage the initiation of a clinical trial to prospectively validate these outcomes.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Buerki R.A.
        • Horbinski C.M.
        • Kruser T.
        • et al.
        An overview of meningiomas.
        Future Oncol. 2018; 14: 2161-2177
        • Fathi A.-R.
        • Roelcke U.
        Meningioma.
        Curr Neurol Neurosci Rep. 2013; 13: 337
        • Rogers L.
        • Barani I.
        • Chamberlain M.
        • et al.
        Meningiomas: Knowledge base, treatment outcomes, and uncertainties. A rano review.
        J Neurosurg. 2015; 122: 4-23
        • Asgharian B.
        • Chen Y.-J.
        • Patronas N.J.
        • et al.
        Meningiomas may be a component tumor of multiple endocrine neoplasia type 1.
        Clin Can Res. 2004; 10: 869-880
        • Lee S.
        • Karas P.J.
        • Hadley C.C.
        • et al.
        The role of merlin/nf2 loss in meningioma biology.
        Cancers. 2019; 11: 1633
        • Backer-Grøndahl T.
        • Moen B.H.
        • Torp S.H.
        The histopathological spectrum of human meningiomas.
        Int J Clin Exp Pathol. 2012; 5: 231
        • Kshettry V.R.
        • Ostrom Q.T.
        • Kruchko C.
        • et al.
        Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the united states.
        Neuro Oncol. 2015; 17: 1166-1173
        • Walcott B.P.
        • Nahed B.V.
        • Brastianos P.K.
        • et al.
        Radiation treatment for who grade II and III meningiomas.
        Front Oncol. 2013; 3: 227
        • Hwang K.L.
        • Hwang W.L.
        • Bussière M.R.
        • et al.
        The role of radiotherapy in the management of high-grade meningiomas.
        Chin Clin Oncol. 2017; 6 (S5)
        • Kaur G.
        • Sayegh E.T.
        • Larson A.
        • et al.
        Adjuvant radiotherapy for atypical and malignant meningiomas: A systematic review.
        Neuro Oncol. 2014; 16: 628-636
        • Minniti G.
        • Amichetti M.
        • Enrici R.M.
        Radiotherapy and radiosurgery for benign skull base meningiomas.
        Radiat Oncol. 2009; 4: 1-11
        • Weber D.C.
        • Ares C.
        • Villa S.
        • et al.
        Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase II parallel non-randomized and observation study (EORTC 22042-26042).
        Radiother Oncol. 2018; 128: 260-265
        • Jenkinson M.D.
        • Javadpour M.
        • Haylock B.J.
        • et al.
        The ROAM/EORTC-1308 trial: Radiation versus observation following surgical resection of atypical meningioma: Study protocol for a randomised controlled trial.
        Trials. 2015; 16: 1-8
        • Santacroce A.
        • Walier M.
        • Régis J.
        • et al.
        Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients.
        Neurosurgery. 2012; 70: 32-39
        • Kondziolka D.
        • Mathieu D.
        • Lunsford L.D.
        • et al.
        Radiosurgery as definitive management of intracranial meningiomas.
        Neurosurgery. 2008; 62: 53-60
        • Simpson D.
        The recurrence of intracranial meningiomas after surgical treatment.
        J Neurol, Neurosurg, Psychiatry. 1957; 20: 22
        • Rogers C.L.
        • Won M.
        • Vogelbaum M.A.
        • et al.
        High-risk meningioma: Initial outcomes from NRG oncology/RTOG 0539.
        Int J Radiat Oncol Biol Phys. 2020; 106: 790-799
        • Rogers L.
        • Zhang P.
        • Vogelbaum M.A.
        • et al.
        Intermediate-risk meningioma: Initial outcomes from NRG oncology RTOG 0539.
        J Neurosurg. 2017; 129: 35-47
        • Aghi M.K.
        • Carter B.S.
        • Cosgrove G.R.
        • et al.
        Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.
        Neurosurgery. 2009; 64: 56-60
        • Lundin P.
        • Pedersen F.
        Volume of pituitary macroadenomas: Assessment by MRI.
        J Comput Assist Tomogr. 1992; 16: 519-528
        • Miller J.A.
        • Bennett E.E.
        • Xiao R.
        • et al.
        Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis.
        Int J Radiat Oncol Biol Phys. 2016; 96: 1060-1069
        • Huang R.Y.
        • Bi W.L.
        • Weller M.
        • et al.
        Proposed response assessment and endpoints for meningioma clinical trials: Report from the response assessment in neuro-oncology working group.
        Neuro Oncol. 2019; 21: 26-36
        • Rogers L.
        • Zhang P.
        • Vogelbaum M.A.
        • et al.
        Erratum. Intermediate-risk meningioma: Initial outcomes from NRG oncology RTOG 0539.
        J Neurosurg. 2018; 129 (1650)
        • Davidson-Pilon C.
        Lifelines: Survival analysis in python.
        J Open Source Softw. 2019; 4: 1317
        • Pedregosa F.
        • Varoquaux G.
        • Gramfort A.
        • et al.
        Scikit-learn: Machine learning in python.
        J Mach Learn Res. 2011; 12: 2825-2830
        • Tosi S.
        Matplotlib for Python Developers.
        Packt Publishing Ltd, Birmingham, UK2009
        • Song Y.-Y.
        • Ying L.
        Decision tree methods: Applications for classification and prediction.
        Shanghai Arch Psychiatry. 2015; 27: 130
        • Strobl C.
        • Malley J.
        • Tutz G.
        An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging, and random forests.
        Psychol Methods. 2009; 14: 323
        • Kudus A.
        Decision tree for competing risks survival probability in breast cancer study.
        2008
        • Pölsterl S.
        Scikit-survival: A library for time-to-event analysis built on top of scikit-learn.
        J Mach Learn Res. 2020; 21: 1-6
        • Vock D.M.
        • Wolfson J.
        • Bandyopadhyay S.
        • et al.
        Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting.
        J Biomed Inform. 2016; 61: 119-131
        • Magill S.T.
        • Young J.S.
        • Chae R.
        • et al.
        Relationship between tumor location, size, and who grade in meningioma.
        Neurosurg Focus. 2018; 44: E4
        • Näslund O.
        • Skoglund T.
        • Farahmand D.
        • et al.
        Indications and outcome in surgically treated asymptomatic meningiomas: A single-center case-control study.
        Acta Neurochir (Wein). 2020; : 1-9
        • Yano S.
        • Kuratsu J-i
        Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience.
        J Neurosurg. 2006; 105: 538-543
        • Kelly P.
        • Mannarino E.
        • Lewis J.
        • et al.
        Defining the target for radiation therapy of meningiomas following resection: A multidisciplinary study of inter-observer variability.
        Int J Radiat Oncol Biol Phys. 2011; 81: S36-S37
        • Jagannathan J.
        • Oskouian R.J.
        • Yeoh H.K.
        • et al.
        Molecular biology of unreresectable meningiomas: Implications for new treatments and review of the literature.
        Skull Base. 2008; 18: 173
        • Maíllo A.
        • Orfao A.
        • Sayagués J.M.
        • et al.
        New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology.
        J Clin Oncol. 2003; 21: 3285-3295
        • Merchant T.E.
        • Pollack I.F.
        • Loeffler J.S.
        Brain tumors across the age spectrum: Biology, therapy, and late effects.
        Semin Radiat Oncol. 2010; 20: 58-66
        • Hwang W.L.
        • Marciscano A.E.
        • Niemierko A.
        • et al.
        Imaging and extent of surgical resection predict risk of meningioma recurrence better than who histopathological grade.
        Neuro Oncol. 2016; 18: 863-872
        • Arrieta O.
        • Garcia E.
        • Guevara P.
        • et al.
        Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma.
        Cancer. 2002; 94: 3210-3218
        • Budohoski K.P.
        • Clerkin J.
        • Millward C.P.
        • et al.
        Predictors of early progression of surgically treated atypical meningiomas.
        Acta Neurochir (Wein). 2018; 160: 1813-1822
        • Chohan M.O.
        • Ryan C.T.
        • Singh R.
        • et al.
        Predictors of treatment response and survival outcomes in meningioma recurrence with atypical or anaplastic histology.
        Neurosurgery. 2018; 82: 824-832
        • Choy W.
        • Ampie L.
        • Lamano J.B.
        • et al.
        Predictors of recurrence in the management of chordoid meningioma.
        J Neurooncol. 2016; 126: 107-116
        • Ildan F.
        • Erman T.
        • Göçer A.İ.
        • et al.
        Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: A multivariate analysis in the midterm follow-up.
        Skull Base. 2007; 17: 157
        • Olar A.
        • Wani K.M.
        • Sulman E.P.
        • et al.
        Mitotic index is an independent predictor of recurrence-free survival in meningioma.
        Brain Pathol. 2015; 25: 266-275
        • Nanda A.
        • Bir S.C.
        • Konar S.
        • et al.
        Outcome of resection of who grade ii meningioma and correlation of pathological and radiological predictive factors for recurrence.
        J Clin Neurosci. 2016; 31: 112-121
        • Ryu H.-S.
        • Moon K.-S.
        • Lee K.-H.
        • et al.
        Recurred intracranial meningioma: A retrospective analysis for treatment outcome and prognostic factor.
        Brain Tumor Res Treat. 2017; 5: 54-63
        • Kuratsu J-i
        • Kochi M.
        • Ushio Y.
        Incidence and clinical features of asymptomatic meningiomas.
        J Neurosurg. 2000; 92: 766-770
        • Chao S.T.
        • Koyfman S.A.
        • Woody N.
        • et al.
        Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1738-1743

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.